Goal Achievement After a Change to Vortioxetine in Adults with Major Depressive Disorder
This study is sponsored by Takeda Pharmaceuticals and is designed to determine the effectiveness of treatment with vortioxetine on goal achievement in individuals with Major Depressive Disorder (MDD). Participants will be:
- Men or women, aged 18 to 65 years, who are able to read and understand English
- Individuals with MDD as the primary psychiatric diagnosis who are changing from another antidepressant to vortioxetine per routine care
This study involves setting goals that are important to the participant and monitoring mood and progress toward those goals. The study lasts up to 19 weeks, which includes approximately five visits to the lab and three phone contacts.
This study has received approval from: IRBMED HUM00128493